Subscribe to RSS
DOI: 10.1055/s-2008-1026058
Running Performance as a Function of the Dose-Response Relationship to β-Adrenoceptor Blockade*
* This study was supported by grants from the Swedish Medical Research Council (No. 4251), the Research Council of the Swedish Sports Federation and ICI-Pharma Sweden.Publication History
Publication Date:
14 March 2008 (online)
![](https://www.thieme-connect.de/media/sportsmed/198201/lookinside/thumbnails/10.1055-s-2008-1026058-1.jpg)
Abstract
There is a discrepancy between the effect of β-blockade on exercise heart rate and the effect on exercise capacity. Thus, it was of interest to study the dose-response relationship between an unselective (propranolol) and a β1-selective (atenolol) blocker and endurance exercise performance. Nine habitually active males ran their own jogging route 10 times and the distances of the routes ranged between 4000 and 10000 m. Placebo (twice), 25, 50, 75, and 100 mg of atenolol and 40, 80, 120, and 160 mg of propranolol were administered orally with a double-blind, crossover procedure. After each experiment, running time and rate of perceived exertion (RPE) were registered. Small drug doses markedly affected exercise heart rates yet such doses minimally affected running performance when on the β1 selective blocker. With 160 mg propranolol, a greater exercise impairment occurred than with 100 mg atenolol (P < 0.05). RPE data suggested that drug treatment induced an increased subjective feeling of fatigue in addition to the impaired performance, and these changes were positively related (r = 0.66, P < 0.05). Impairment of exercise performance during acute β-blockade is evidently not related solely to the effect on heart rate. The nature of other drug effects is presently unclear although there is evidence that the metabolic profile of the muscle is implicated.
Key words
β-adrenergic blockade - dose response - muscle fiber types - endurance exercise - bradycardia - RPE